Literature DB >> 28077656

Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Silvie Van den Hoecke1,2, Katrin Ehrhardt3, Annasaheb Kolpe1,2, Karim El Bakkouri1,2, Lei Deng1,2, Hendrik Grootaert1,4, Steve Schoonooghe5,6, Anouk Smet1,2, Mostafa Bentahir1,2, Kenny Roose1,2, Michael Schotsaert1,2, Bert Schepens1,2, Nico Callewaert1,4, Falk Nimmerjahn7, Peter Staeheli3, Hartmut Hengel3, Xavier Saelens8,2.   

Abstract

The ectodomain of matrix protein 2 is a universal influenza A virus vaccine candidate that provides protection through antibody-dependent effector mechanisms. Here we compared the functional engagement of Fcγ receptor (FcγR) family members by two M2e-specific monoclonal antibodies (MAbs), MAb 37 (IgG1) and MAb 65 (IgG2a), which recognize a similar epitope in M2e with similar affinities. The binding of MAb 65 to influenza A virus-infected cells triggered all three activating mouse Fcγ receptors in vitro, whereas MAb 37 activated only FcγRIII. The passive transfer of MAb 37 or MAb 65 in wild-type, Fcer1g-/-, Fcgr3-/-, and Fcgr1-/-Fcgr3-/- BALB/c mice revealed the importance of these receptors for protection against influenza A virus challenge, with a clear requirement of FcγRIII for IgG1 MAb 37 being found. We also report that FcγRIV contributes to protection by M2e-specific IgG2a antibodies.IMPORTANCE There is increased awareness that protection by antibodies directed against viral antigens is also mediated by the Fc domain of these antibodies. These Fc-mediated effector functions are often missed in clinical assays, which are used, for example, to define correlates of protection induced by vaccines. The use of antibodies to prevent and treat infectious diseases is on the rise and has proven to be a promising approach in our battle against newly emerging viral infections. It is now also realized that Fcγ receptors significantly enhance the in vivo protective effect of broadly neutralizing antibodies directed against the conserved parts of the influenza virus hemagglutinin. We show here that two M2e-specific monoclonal antibodies with close to identical antigen-binding specificities and affinities have a very different in vivo protective potential that is controlled by their capacity to interact with activating Fcγ receptors.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Fcγ receptors; IgG antibody isotype; M2e; influenza A virus; mechanism of protection; viral infection

Mesh:

Substances:

Year:  2017        PMID: 28077656      PMCID: PMC5355615          DOI: 10.1128/JVI.02500-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Authors:  Nicole Schmitz; Roger R Beerli; Monika Bauer; Andrea Jegerlehner; Klaus Dietmeier; Melanie Maudrich; Paul Pumpens; Philippe Saudan; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

Review 3.  The function of Fcγ receptors in dendritic cells and macrophages.

Authors:  Martin Guilliams; Pierre Bruhns; Yvan Saeys; Hamida Hammad; Bart N Lambrecht
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

4.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

5.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

6.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 7.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

8.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

9.  Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages.

Authors:  Suki M Y Lee; Jennifer L Gardy; C Y Cheung; Timothy K W Cheung; Kenrie P Y Hui; Nancy Y Ip; Y Guan; Robert E W Hancock; J S Malik Peiris
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

10.  M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.

Authors:  Lorena Itatí Ibañez; Kenny Roose; Marina De Filette; Michael Schotsaert; Jessica De Sloovere; Stefan Roels; Charlotte Pollard; Bert Schepens; Johan Grooten; Walter Fiers; Xavier Saelens
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more
  40 in total

Review 1.  Inactivated influenza virus vaccines: the future of TIV and QIV.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Curr Opin Virol       Date:  2017-05-12       Impact factor: 7.090

2.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

Review 3.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

4.  Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.

Authors:  Lei Deng; Jong R Kim; Timothy Z Chang; Han Zhang; Teena Mohan; Julie A Champion; Bao-Zhong Wang
Journal:  Virology       Date:  2017-06-13       Impact factor: 3.616

Review 5.  Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?

Authors:  Cassandra M Berry
Journal:  Hum Vaccin Immunother       Date:  2017-11-07       Impact factor: 3.452

6.  Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines.

Authors:  Liang Ye; Annette Ohnemus; Li Ching Ong; Hans Henrik Gad; Rune Hartmann; Nils Lycke; Peter Staeheli
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

7.  Identification and Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus.

Authors:  Philipp Kolb; Steven Sijmons; Matthew R McArdle; Husam Taher; Jennie Womack; Colette Hughes; Abigail Ventura; Michael A Jarvis; Christiane Stahl-Hennig; Scott Hansen; Louis J Picker; Daniel Malouli; Hartmut Hengel; Klaus Früh
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

8.  Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Authors:  E R Job; M Schotsaert; L I Ibañez; A Smet; T Ysenbaert; K Roose; M Dai; C A M de Haan; H Kleanthous; T U Vogel; X Saelens
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

9.  Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.

Authors:  Meito Shibuya; Taiki Aoshi; Etsushi Kuroda; Yasuo Yoshioka
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

10.  An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.

Authors:  Jason R Wilson; Jessica A Belser; Juliana DaSilva; Zhu Guo; Xiangjie Sun; Shane Gansebom; Yaohui Bai; Thomas J Stark; Jessie Chang; Paul Carney; Min Z Levine; John Barnes; James Stevens; Taronna R Maines; Terrence M Tumpey; Ian A York
Journal:  Virology       Date:  2017-09-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.